Racura Successfully PK Bridges RC110 RC220
Released
Released
Announcement PDF
Racura Oncology Ltd | ABN 61 149 318 749 | L36 1 Macquarie Place Sydney NSW 2000 Australia
+61 2 8051 3043 | info@racuraoncology.com | www.racuraoncology.com 1
ASXAnnouncement
Racura Successfully Demonstrates
Pharmacokinetic Equivalence of
RC110 & RC220
§ A nonclinical pharmacokinetic bridging study has found that RC220 and the earlier RC110
formulation of (E,E)-bisantrene deliver equivalent systemic drug exposure
§ Ratios of peak and total drug exposure of (E,E)-bisantrene fell within the pre-specified
equivalence range of 0.80–1.25, meeting regulatory standards for formulation equivalence
§ These nonclinical data support the use of the established RC110 clinical dataset and established
dosing levels in the clinical development of RC220, including the Phase 2b/3 EMILI trial
17 November 2026
Racura Oncology Ltd (“Racura” or the “Company”) is pleased to announce the results of a Good Laboratory
Practice (GLP) nonclinical pharmacokinetic (PK) bridging study comparing RC220, the Company’s
proprietary formulation of (E,E)-bisantrene, with RC110, the earlier Racura formulation used in two
investigator-sponsored Phase 2 clinical trials in relapsed or refractory (returned or treatment-resistant)
acute myeloid leukaemia (R/R AML). The study found RC220 and RC110 produced equivalent systemic
exposure to (E,E)-bisantrene.
Pharmacokinetics describes how the body processes a drug over time, including the concentration it
reaches in the bloodstream and how long it remains before being cleared. A PK bridging study tests
whether two formulations of the same active drug produce the same drug exposure, so that clinical
experience gained with one formulation can inform the development of the other.
Racura CEO and MD, Dr Daniel Tillett, commented: “This nonclinical study was designed to answer a critical
question for our RC220 clinical programs: does RC220 deliver the same drug exposure as RC110? The
results of this GLP PK study show the two formulations delivered equivalent exposure to (E,E)-bisantrene.
The findings provide an important bridge to the clinical experience with RC110, which produced a 40%
response rate in two separate Phase 2 trials in heavily pre-treated AML patients. This bridging study supports
our plans to evaluate RC220 in patients with AML in the Phase 2b/3 EMILI trial as well as our HARNESS and
CPACS clinical programs. I wish to thank the Racura team and our study partners for the careful execution
of this important work.”
Racura Oncology Ltd | ABN 61 149 318 749 | L36 1 Macquarie Place Sydney NSW 2000 Australia
+61 2 8051 3043 | info@racuraoncology.com | www.racuraoncology.com 2
Nonclinical Bridging PK Study Design & Results
RC110 and RC220 contain the same active ingredient, (E,E)-bisantrene, and differ only in their formulation
excipients (non-drug ingredients). RC220 was developed to allow bisantrene to be given through a
peripheral vein in the arm or leg, rather than requiring the use of a central line (a catheter placed in a large
vein near the heart).
The nonclinical bridging study in six animals used a crossover design, in which each animal received
intravenous infusions of both RC110 and RC220 in random order, separated by a drug-free washout period,
and so served as its own control. Frequent blood sampling was used to measure plasma (E,E)-bisantrene
concentrations over time.
Equivalence was assessed using the standard regulatory approach for comparing drug formulations, which
is the ratio of average RC220 to RC110 exposure (the geometric mean ratio, GMR, where 1.00 means
identical exposure) and its 90% confidence interval (CI), against a pre-specified range of 0.80–1.25.1,2
Across three consecutive days of dosing, the 90% CIs for both peak plasma concentration (Cmax) and total
exposure (area under the concentration–time curve, AUC) fell within this range on every day (Figure 1),
with GMRs ranging from 0.971 to 1.057.
Figure 1. RC220 and RC110 deliver equivalent exposure to (E,E)-bisantrene with repeat daily dosing. (A) Geometric mean
peak plasma concentration (Cmax) of (E,E)-bisantrene after each of three once-daily 1 mg/kg intravenous doses (30-minute
infusion) of RC110 or RC220 in male Beagle dogs (n = 6, two-period crossover with a five-day washout). (B) Ratio of RC220
to RC110 exposure (geometric mean ratio with 90% confidence interval) for Cmax and AUC on each dosing day. The shaded
band is the pre-specified equivalence range of 0.80–1.25; a ratio of 1.00 indicates identical exposure.
Racura Oncology Ltd | ABN 61 149 318 749 | L36 1 Macquarie Place Sydney NSW 2000 Australia
+61 2 8051 3043 | info@racuraoncology.com | www.racuraoncology.com 3
Significance for Racura’s RC220 Clinical Programs
RC110 was used in two investigator-sponsored clinical trials in R/R AML conducted at the Sheba Medical
Center, Israel. In a Phase 2 trial, RC110 given alone produced an overall response rate (complete or partial
responses) of 40% in 10 patients (ASX Announcement: 16 June 2020).3
In a Phase 1b/2 trial, RC110
combined with fludarabine and clofarabine produced a response in 6 of 15 evaluable patients (ASX
Announcement: 4 August 2025).4
These clinical results underpin Racura’s plan to advance RC220 in AML
through the Phase 2b/3 EMILI trial (ASX Announcement: 17 November 2025).
Both AML trials gave RC110 as a daily infusion over multiple consecutive days. These nonclinical PK
equivalence data, together with the identical active ingredient in the two products, support applying the
RC110 clinical experience to the future development of RC220.
References
1. US Food and Drug Administration. Statistical approaches to establishing bioequivalence: guidance for industry. 2001
https://www.fda.gov/media/70958/download
2. European Medicines Agency. Guideline on the investigation of bioequivalence. CPMP/EWP/QWP/1401/98 Rev.
1/Corr. 2010 https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-investigation-
bioequivalence-rev1_en.pdf
3. Canaani J, Danylesko I, Shemtov N, Zlotnick M, Lozinsky K, Benjamini O, et al. A phase II study of bisantrene in
patients with relapsed/refractory acute myeloid leukemia. Eur J Haematol. 2021;106(2):260-6.
doi:10.1111/ejh.13544
4. Danylesko I, Shimoni A, Avigdor A, Kedmi M, Amitai I, Shem-Tov N, et al. Bisantrene in combination with fludarabine
and clofarabine as salvage therapy for adult patients with refractory or relapsed acute myeloid leukaemia (AML)—an
open-label, phase I/II study. Br J Haematol. 2025;207(4):1425-34. doi:10.1111/bjh.70035
-ENDS-
Racura Oncology Ltd | ABN 61 149 318 749 | L36 1 Macquarie Place Sydney NSW 2000 Australia
+61 2 8051 3043 | info@racuraoncology.com | www.racuraoncology.com 4
Q&A
Why are PK bridging studies undertaken when a drug is reformulated?
When a drug is reformulated with different inactive ingredients, evidence is needed that the new product
delivers the same exposure to the active drug before experience with the older formulation can be relied
on. Showing equivalent exposure in a human or GLP animal study supports using earlier clinical experience
to guide the development of a new formulation, such as RC220.
How does this study impact Racura’s other RC220 trials?
RC220 is already being administered to patients through a peripheral vein in both the Phase 1 CPACS trial
in solid tumours and the Phase 1 HARNESS trial in lung cancer. While the results of this bridging study are
not essential for the running of these solid tumour trials, they may help accelerate the dose escalation
stage or support earlier progression to later-stage trials.
What does a ratio “within 0.80–1.25” mean in an equivalence study?
The 90% confidence interval shows the range in which the true ratio of RC220 to RC110 exposure is likely
to sit. Regulators such as the FDA or EMA treat two formulations as equivalent when the whole of this
interval lies between 0.80 and 1.25, meaning the exposure differs by no more than 20% in either
direction.1,2
In this study, every interval for repeat daily dosing met this standard.
Why were dogs used, and why repeat daily dosing?
Dogs are a standard species for nonclinical PK and safety studies, and the dog was one of the two species
used in the GLP toxicology program for RC220 (ASX Announcement: 26 June 2024). Repeat daily dosing
was examined because RC110 was given daily over several consecutive days in the earlier AML trials, and
the same approach is planned for RC220. No dog was harmed in this PK study, as the RC220 and RC110
doses used were well below the level that causes harm.
Does this mean RC220 is certain to work in AML patients?
No. This nonclinical study measured how much drug reached the bloodstream in dogs, not its anticancer
activity in patients. While this study supports using the RC110 AML clinical data and dose experience to
guide the development of RC220, the safety and efficacy of RC220 will need to be established in AML.
What happens next?
Racura will use these results to support regulatory submissions for AML and other clinical indications.
Racura Oncology Ltd | ABN 61 149 318 749 | L36 1 Macquarie Place Sydney NSW 2000 Australia
+61 2 8051 3043 | info@racuraoncology.com | www.racuraoncology.com 5
About Racura Oncology
Racura Oncology (ASX: RAC) is a late-stage clinical biopharmaceutical company with a mission to silence
cancer.
Racura’s lead asset, (E,E)-bisantrene, is a clinically derisked small-molecule anticancer agent that
primarily acts by stabilising G4-DNA and RNA structures, driving potent inhibition of c-MYC gene
expression, a key cancer gene dysregulated in up to 70% of all cancers. Bisantrene has shown therapeutic
activity in cancer patients and has a well-characterised safety profile. Racura’s discoveries have supported
composition-of-matter IP filings that, if granted, could provide up to 20 years of patent protection for (E,E)-
bisantrene.
Racura is advancing RC220, its proprietary formulation of (E,E)-bisantrene, to address significant unmet
need across multiple MYC-driven oncology indications. The Company’s clinical programs include the EMILI
Phase 2b/3 trial in acute myeloid leukaemia, the HARNESS Phase 1 trial in combination with osimertinib
for EGFRm NSCLC, and the CPACS Phase 1 trial in combination with doxorubicin, where Racura aims to
deliver both anthracycline cardioprotection and enhanced anticancer activity.
Racura has collaborated with Astex, Emory University, Purdue University, MD Anderson Cancer Center,
Sheba Medical Center, University of North Carolina School of Medicine, University of Wollongong, and
University of Newcastle. Racura is actively exploring partnerships, licence agreements, and potential
commercial merger and acquisition opportunities to accelerate global patient access to RC220.
Learn more at www.racuraoncology.com.
If you have any questions on this announcement, or any past Racura Oncology announcements, please
visit the Company’s Interactive Announcements page.
Racura encourages all investors to go paperless by registering their details with the Company’s share
registry, Automic Registry Services, at www.automicgroup.com.au.
Release authorised by Media Contact
Daniel Tillett, CEO/MD Cherie Hartley +61 418 737 020
info@racuraoncology.com cherie.hartley@irdepartment.com.au
Share your feedback
Discover